🇪🇺EU · EMAApplication withdrawnATC: H02AB02

Dexamethasone Taw(Dexamethasone (sodium phosphate))

COVID-19 virus infection;Brain Edema;Respiratory Distress Syndrome, Adult;Asthma;Skin Diseases;Autoimmune Diseases;Arthritis;Vomiting;Inflammation;Eye Diseases;Postoperative Nausea and Vomiting

Marketing Authorisation Holder: Taw Pharma (Ireland) Ltd

INN: dexamethasone phosphate

Indication

Indicated for cerebral oedema, post-traumatic shock-lung syndrome, asthma, skin diseases, autoimmune diseases, rheumatoid arthritis, prophylaxis and treatment of post-operative or cytostatic-induced vomiting, treatment of COVID-19, eye inflammation and infection.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Dexamethasone Taw — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Dexamethasone Taw Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.